Skip to content

Independent medical information for international patients

Menu

Disease

Leukaemia白血病

ICD-10: C91–C95 — Leukaemia

Group: Cancer Specialty: Hematology

Key figures

Published values only. Every tile opens the section that carries its source, its year and its caliber.

Disease details

Standard Chinese name
白血病
English name
Leukaemia

Values written in Chinese are quoted as published by the source.

Also known as

  • Leukaemia
  • Leukemia

Treatment cost ranges

Every range below is published on one billing basis: Pre-reimbursement 医保报销前. The sources publish no post-reimbursement figure, so none is shown here.

Treatment path Cost range Price basis Data year
Chemotherapy 化疗 20000 – 20000 CNY Condition package price 病种打包全包价 2020
Chemotherapy 化疗 54000 – 54000 CNY Condition package price 病种打包全包价 2020
Chemotherapy 化疗 95000 – 95000 CNY Condition package price 病种打包全包价 2020
Chemotherapy 化疗 87000 – 87000 CNY Condition package price 病种打包全包价 2020
Chemotherapy 化疗 100000 – 100000 CNY Condition package price 病种打包全包价 2020
Chemotherapy 化疗 7000 – 7000 CNY Condition package price 病种打包全包价 2020
Chemotherapy 化疗 9000 – 9000 CNY Condition package price 病种打包全包价 2020
Chemotherapy 化疗 36000 – 36000 CNY Condition package price 病种打包全包价 2020
Chemotherapy 化疗 10500 – 10500 CNY Condition package price 病种打包全包价 2020
Chemotherapy 化疗 42200 – 42200 CNY Condition package price 病种打包全包价 2020
Chemotherapy 化疗 52700 – 52700 CNY Condition package price 病种打包全包价 2020
Chemotherapy 化疗 95000 – 95000 CNY Condition package price 病种打包全包价 2020
Chemotherapy 化疗 70800 – 70800 CNY Condition package price 病种打包全包价 2020
Chemotherapy 化疗 28000 – 28000 CNY Condition package price 病种打包全包价 2020
Chemotherapy 化疗 11500 – 11500 CNY Condition package price 病种打包全包价 2020
Chemotherapy 化疗 66300 – 66300 CNY Condition package price 病种打包全包价 2020
Chemotherapy 化疗 20800 – 20800 CNY Condition package price 病种打包全包价 2020
Chemotherapy 化疗 36500 – 36500 CNY Condition package price 病种打包全包价 2020
Chemotherapy 化疗 30100 – 30100 CNY Condition package price 病种打包全包价 2020
Chemotherapy 化疗 50000 – 50000 CNY Condition package price 病种打包全包价 2020
Chemotherapy 化疗 72000 – 72000 CNY Condition package price 病种打包全包价 2020
Chemotherapy 化疗 30800 – 30800 CNY Condition package price 病种打包全包价 2020
Chemotherapy 化疗 43300 – 43300 CNY Condition package price 病种打包全包价 2020
Chemotherapy 化疗 72000 – 72000 CNY Condition package price 病种打包全包价 2020
Chemotherapy 化疗 95400 – 95400 CNY Condition package price 病种打包全包价 2020

The bars share one scale across the rows above: each starts at that row's lower published figure and ends at its upper one. The highest upper figure on this page is 100000 CNY. Each row keeps its own data year and caliber.

25 cost ranges for this condition, each with its source on the row page.

Values written in Chinese are quoted as published by the source.

See all cost ranges →

Five-year survival

5-year survival rate 30.6% 95% CI 30.2–31.1

Population
Overall (all stages combined) · Age-standardised relative survival 总体（全分期合并）· 年龄标准化相对生存率
Period
2019–2021
Publisher
National Cancer Center 国家癌症中心
Value nature
Estimated value (hybrid analysis) 估计值（混合法）
Registry scope
281 population-based cancer registries 281 个肿瘤登记处
Stage data availability
Not published

Values written in Chinese are quoted as published by the source.

See all survival rates →

How to read this figure. It is published for all stages combined, so it is an average over everyone in the national registry data rather than a prognosis for one person. For most cancers, the stage at diagnosis is the strongest single factor behind survival differences: survival is generally higher when the cancer is found at an earlier stage and lower when it is found later. Comparisons between cancers are also shaped by how early or late each one tends to be diagnosed, so a lower figure does not by itself mean worse care.

The figure is relative survival: it compares people diagnosed with this cancer against people of the same age and sex in the general population, and it is age-standardised, so it is not the share of patients still alive after five years. It is published as an estimated value (hybrid analysis) because registry reports arrive with a lag, so the National Cancer Center modelled the most recent period. For context, the same source publishes 43.7% five-year relative survival for all cancers combined in 2019–2021.

Hospitals with a published record for this condition

Selected using official public data sources

These hospitals are selected from official public data sources — the Fudan University hospital specialty reputation rankings, the national key clinical specialties list and national clinical research centres — so each line on a card can be checked against its published source. This is not a paid or promoted listing.

How these hospitals were selected

Admission. A hospital is listed for a condition when the specialty that condition is filed under carries at least one of: a place or a nomination in the Fudan University hospital specialty reputation ranking; a national key clinical specialty record at level A, B or C; or a national clinical research centre or a state key laboratory in that specialty. JCI accreditation is shown as a badge; it never decides admission and it never decides order.

Order. Step 1: a Fudan place between 1 and 10 for the specialty. Step 2: another Fudan place, or a nomination. Step 3: a level-A national key clinical specialty. Step 4: a level-B national key clinical specialty. Step 5: a national clinical research centre or a state key laboratory in the specialty, a centre before a laboratory. Step 6: a level-C national key clinical specialty, which is a record we publish without an independent official source and which is therefore listed after the others.

Ties. Within one step: the better Fudan place first, then the stronger key-specialty level (A before B before C), then the province, then the city, then the hospital name - the same province-city-name order the hospital directory uses. At most eight hospitals are listed.

When the list is short. Five hospitals or more: the first eight are listed. Three or four: all of them are listed, and a further fold adds the remaining records up to eight, each carrying its evidence level. One or two: the same, with that fold open and a line stating how many hospitals have a strong public record. None: the page states that no strong public record was found and links to the specialty directory. A place, an institution or a count is never invented to fill the list.

The Fudan rankings are the hospital specialty reputation ranking most widely recognised by Chinese clinicians, published annually by Fudan University's hospital management institute.

  1. West China Hospital, Sichuan University四川大学华西医院

    Chengdu 成都市

    National key clinical specialty

    Also ranked: General Surgery #3, Thoracic Surgery #4, Urology #2 (tied) in the Fudan list.

  2. Qilu Hospital of Shandong University山东大学齐鲁医院

    Jinan 济南市

    National key clinical specialty

    Also ranked: Gynecology #7 (tied), Otorhinolaryngology nominated, Gastroenterology nominated in the Fudan list.

  3. The First Affiliated Hospital, Zhejiang University School of Medicine浙江大学医学院附属第一医院

    Hangzhou 杭州市

    National key clinical specialty

    Also ranked: General Surgery #7, Urology #9, Infectious Diseases 传染感染 #2 in the Fudan list.

  4. Ruijin Hospital上海交通大学医学院附属瑞金医院

    Shanghai 上海市

    National key clinical specialty

    Also ranked: General Surgery #4, Thoracic Surgery #7 (tied), Respiratory Medicine #5 in the Fudan list.

  5. Beijing Hospital北京医院

    Beijing 北京市

    National key clinical specialty

    Also ranked: Urology nominated in the Fudan list.

  6. Peking University People's Hospital北京大学人民医院

    Beijing 北京市

    National key clinical specialty

    Also ranked: General Surgery #10, Thoracic Surgery #7, Gynecology #7 in the Fudan list.

  7. Peking University Third Hospital北京大学第三医院

    Beijing 北京市

    National key clinical specialty

    Also ranked: Gynecology #4, Urology nominated, Gastroenterology nominated in the Fudan list.

  8. Anhui Provincial Hospital中国科学技术大学附属第一医院（安徽省立医院）

    Hefei 合肥市

    National key clinical specialty

    Also ranked: General Surgery nominated, Otorhinolaryngology nominated in the Fudan list.

Clinical trials (investigational treatments)

In addition to standard care, clinical research studies for Leukaemia may currently be open to participants in China. The treatments under study have not been approved by the regulator as standard therapy — they are clinical research, not routine treatment. Each record names the lead investigator and the hospital running the study. If you are interested, contact the hospital to ask about eligibility and choose whether to apply.

  1. Study The Efficacy and Safety of BCL-2 Inhibitors Combined with the HyperCVAD Regimen in the Treatment of Newly Diagnosed T-lymphoblastic Leukemia/ Lymphoma

    Lead investigator
    Xianmin Song, MD · Investigator Official Title
    Hospital
    Shanghai General Hospital
    Status
    Recruiting
    Registry
    NCT06598722

  2. Study To Observe and Evaluate the Efficacy and Safety of Inaticabtagene Autoleucel Injection in the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia in Adults in the Real World

    Hospital
    Peking University People's Hospital
    Status
    Recruiting
    Registry
    NCT06450067

  3. Study A Clinical Study Evaluating the Safety and Efficacy of IL-15-armored Novel CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma and Plasma Cell Leukemia

    Lead investigator
    FengYan Jin · Clinical Professor of Hematology Department
    Hospital
    The First Hospital of Jilin University
    Status
    Recruiting
    Registry
    NCT07509086

  4. Study Avapritinib Combined With Standard Therapy for the Treatment of Newly Diagnosed KIT Mutation Acute Myeloid Leukemia With t(8;21)(q22;q22.1); Inv(16)(p13.1q22) or t(16;16)(p13.1;q22): a Prospective, Multi-center, Single-arm, Two-cohorts Study

    Lead investigator
    Chen Suning · Prof.
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT07028073

  5. Study An Open-Label, Multi-Center, Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YK012 in Participants With B-cell Acute Lymphoblastic Leukemia

    Hospital
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Status
    Recruiting
    Registry
    NCT06580301
145 more registered studies

  1. Study A Phase IB Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

    Hospital
    Peking University People's Hospital
    Status
    Recruiting
    Registry
    NCT05091424

  2. Study Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in Pediatric Acute Myeloid Leukaemia: a Prospective Study

    Lead investigator
    Chang Yingjun · Chief Physician
    Hospital
    Peking University People's Hospital
    Status
    Recruiting
    Registry
    NCT06452732

  3. Study Venetoclax-Azacitidine in Combination With Chidamide and CAG Versus 3+7 Regimen in Fit Older Patients With Acute Myeloid Leukaemia：A Multicenter, Randomized, Controlled, Phase 3 Trial

    Lead investigator
    Daihong Liu · Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital
    Hospital
    Chinese PLA General Hospital
    Status
    Recruiting
    Registry
    NCT07514936

  4. Study A Multicenter, Prospective, Randomized Controlled Clinical Study Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in the Treatment of Adult Newly Diagnosed Early Precursor T-cell Acute Lymphoblastic Leukemia (ETP-ALL)

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT06361329

  5. Study An Open-label, Clinical Study of CD7-targeted CAR-T Cells for the Treatment of Measurable Residual Disease of T-lymphoblastic Leukaemia/Lymphoma Post Allogeneic Stem Cell Transplantation

    Lead investigator
    Xiao-Jun Huang · Chief
    Hospital
    Peking University People's Hospital
    Status
    Recruiting
    Registry
    NCT07280494

  6. Study A Multicenter Prospective Clinical Study of Inotuzumab Ozogamicin (INO) in the Treatment of Minimal Residual Disease Recurrent After Hematopoietic Stem Cell Transplantation of Acute Lymphoblastic Leukemia (ALL)

    Lead investigator
    Sheng-Li Xue, MD · Professor
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT05940961

  7. Study A Phase I/IIa, Open-Label Dose Escalation and Dose Expansion Study of Intravenous GFH009 Single Agent and in Combination With Venetoclax and Azacitidine in Patients With Relapsed/Refractory Hematologic Malignancies and High-Risk Newly Diagnosed AML

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT04588922

  8. Study MRD-positive AML: a Prospective, Single-arm, Multicenter Platform Clinical Study

    Hospital
    Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
    Status
    Recruiting
    Registry
    NCT07131059

  9. Study A Clinical Study on the Safety and Effectiveness of Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma

    Lead investigator
    He Huang · Clinical Professor
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT06633341

  10. Study Low-intensity Chemotherapy Combined With Targeted-Immunotherapy for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Prospective Clinical Cohort Study

    Hospital
    Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
    Status
    Recruiting
    Registry
    NCT07493161

  11. Study Clinical Study of CD5 Targeting Chimeric Antigen Receptor NK Cells (CAR-NK) in the Treatment of Relapse/Refractory T-Cell Hematologic Malignancies

    Hospital
    Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
    Status
    Recruiting
    Registry
    NCT06909474

  12. Study Open-label, Dose-escalation Phase 1 Clinical Study of SENL101 Autologous T Cell Injection in the Treatment of Adult Patients With Relapsed or Refractory T-LBL/ALL

    Hospital
    Ruijin Hospital
    Status
    Recruiting
    Registry
    NCT06136364

  13. Study A Multicenter, Single-Arm Clinical Study of the Venetoclax, Ivosidenib, and Azacitidine Triple-Drug Regimen in the Treatment of Chemotherapy-eligible Adult Patients With IDH1-Mutated Acute Myeloid Leukemia.

    Hospital
    Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
    Status
    Recruiting
    Registry
    NCT06611839

  14. Study The Safety and Efficacy for Anti-human CLL-1 CAR-NK Cells in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

    Lead investigator
    Xianmin Song, MD · Doctor
    Hospital
    Shanghai General Hospital
    Status
    Recruiting
    Registry
    NCT06307054

  15. Study A Study of Chidamide With AZA in MRD Positive AML After Transplant

    Lead investigator
    WENG Jian yu · professor
    Hospital
    Guangdong Provincial People's Hospital
    Status
    Recruiting
    Registry
    NCT06066905

  16. Study A Global Multicenter Open Label Randomized Phase III Confirmatory Study of Lisaftoclax (APG-2575) in Combination With Acalabrutinib vs Immunochemotherapy in Patients With Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT06319456

  17. Study Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia

    Lead investigator
    Siqi Li · Chief Technician
    Hospital
    Peking University People's Hospital
    Status
    Recruiting
    Registry
    NCT07537738

  18. Study A Single-arm, Open-label Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of U32 Injection in Patients With Acute Myeloid Leukemia.

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT07036250

  19. Study Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia, a Prospective, Open, Multicenter, Randomized, Control Study (COMPLETE Study)

    Lead investigator
    Xiao-Jun Huang · Prof.
    Hospital
    Peking University People's Hospital
    Status
    Recruiting
    Registry
    NCT06581081

  20. Study Clinical Study on the Safety and Efficacy of Autologous Hematopoietic Stem Cell Transplantation Combined With BCMA-CAR-T in the Treatment of Ultra-high Risk Multiple Myeloma

    Hospital
    Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
    Status
    Recruiting
    Registry
    NCT07109323

  21. Study Clinical Study Protocol to Evaluate the Safety and Efficacy of γδ T Cells for the Prevention of Relapse After Allogeneic Transplantation in Patients With High-risk Acute Myeloid Leukemia

    Lead investigator
    Donghua Zhang · Director
    Hospital
    Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
    Status
    Recruiting
    Registry
    NCT07237230

  22. Study A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults

    Lead investigator
    MEI HENG · Professor
    Hospital
    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Status
    Recruiting
    Registry
    NCT07470073

  23. Study Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Comparison to Consolidation Therapy Based Venetoclax for Elderly Patients With Acute Myeloid Leukemia After First CR

    Lead investigator
    He Huang · Discipline Leader of Bone Marrow Transplant Center
    Hospital
    The First Affiliated Hospital, Zhejiang University School of Medicine
    Status
    Recruiting
    Registry
    NCT06571825

  24. Study Study of the Efficacy and Safety of Venetoclax as Consolidation to Achieve Fix-Duration Treatment in CLL Patients Treated With BTK Inhibitor Monotherapy

    Hospital
    Jiangsu Province Hospital
    Status
    Recruiting
    Registry
    NCT06958705

  25. Study A Perspective, Multicenter, Open-label and Observational Trial for Unrelated Umbilical Cord Blood Stem Cell Microtransplantation Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and Secondary AML.

    Hospital
    Jiangsu Province Hospital
    Status
    Recruiting
    Registry
    NCT05584761

  26. Study The Efficacy and Safety of Homoharringtonine Combined With Venetoclax and Azacitidine Versus Standard Chemotherapy or VA in the Treatment of Acute Myeloid Leukemia With High-risk, a Multicenter, Prospective, Randomized Study

    Hospital
    Nanfang Hospital
    Status
    Recruiting
    Registry
    NCT06810791

  27. Study The Safety and Efficacy of CD19 & CD22 Bispecific CAR T Cells in Treating Relapsed / Refractory B Cell Hematological Tumors

    Lead investigator
    MEI HENG · Proferssor, Cheif Doctor
    Hospital
    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Status
    Recruiting
    Registry
    NCT06735495

  28. Study Haploidentical Hematopoietic Cell Transplantation Combined With an Unrelated Cord Blood Unit for Acute T Cell Lymphoblastic Leukemia Compared to Haploidentical Hematopoietic Cell Transplantation: a Multicenter, Randomized, Open-label Trial

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT06381817

  29. Study A Prospective Cohort Study of a Pediatric-Inspired Chemotherapy Regimen Combined With Venetoclax and Immunotherapy for the Treatment of Adult Ph-Negative Acute Lymphoblastic Leukemia

    Hospital
    Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
    Status
    Recruiting
    Registry
    NCT07495631

  30. Study A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Chinese Patients With B-Cell Malignancies

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT05294731

  31. Study A Randomized, Controlled, Prospective Study on the Efficacy and Safety of Active Immunity Induced by Autologous Peptides for Maintenance Therapy in Acute Myeloid Leukemia (AML)

    Lead investigator
    HuangMeiJuan · Clinical Professor
    Hospital
    Fujian Medical University Union Hospital
    Status
    Recruiting
    Registry
    NCT07551037

  32. Study Assessment of the Safety and Efficacy of Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia: A Single-Arm, Open-Label, Prospective Study

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT06696833

  33. Study A Multicenter, Open-label, Prospective, Randomized Controlled Study to Optimize the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease

    Lead investigator
    Yehui Tan · Professor
    Hospital
    The First Hospital of Jilin University
    Status
    Recruiting
    Registry
    NCT07023588

  34. Study Reduced-dose Anti-thymocyte Globulin Plus Mini-dose Post-transplant Cyclophosphamide for GVHD Prevention in Haploidentical Donor HCT for Hematologic Malignancy

    Lead investigator
    Xiao-Jun Huang · Peking University People's Hospital
    Hospital
    Peking University People's Hospital
    Status
    Recruiting
    Registry
    NCT06984536

  35. Study Exposure-Response and Prognostic Analysis of Venetoclax Therapeutic Drug Monitoring in Newly Diagnosed AML

    Lead investigator
    CHEN Jia · Chief Physician of Hematology. Clinical Professor. Principal Investigator
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT07670130

  36. Study Clinical Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

    Lead investigator
    Chunyan Sun · Professor
    Hospital
    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Status
    Recruiting
    Registry
    NCT06140966

  37. Study A Phase 3, Open-Label, Randomized, Multicenter Study to Evaluate Anti-tumor Efficacy of DZD8586 Versus Investigator's Choice in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    Hospital
    Jiangsu Province Hospital
    Status
    Recruiting
    Registry
    NCT07139873

  38. Study Haploidentical Combined With Cord Blood Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes: A Prospective, Multicenter Clinical Study

    Hospital
    Fujian Medical University Union Hospital
    Status
    Recruiting
    Registry
    NCT07588360

  39. Study The Efficacy of Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia - a Prospective Phase Ⅱ Multicenter Clinical Trial From China

    Hospital
    Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
    Status
    Recruiting
    Registry
    NCT06530576

  40. Study A Phase I Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of APG-3288 in Patients With Relapsed/Refractory Hematological Malignancies

    Hospital
    Henan Cancer Hospital
    Status
    Recruiting
    Registry
    NCT07424833

  41. Study An Open-Label, Single-Arm, Phase II Exploratory Study of ABL and JAK Kinase Inhibitors With Chemotherapy and Venetoclax in Adult Patients With Ph-like ALL

    Hospital
    Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
    Status
    Recruiting
    Registry
    NCT07454226

  42. Study Cord Blood-derived CD70-targeting CAR-NK Cell Therapy for Refractory/Relapsed T Cell Lymphoma and Acute Myeloid Leukemia

    Hospital
    The Second Affiliated Hospital Zhejiang University School of Medicine
    Status
    Recruiting
    Registry
    NCT06696846

  43. Study HEC73543 Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukemia: a Multicenter, Open-label, Randomized Phase 3 Trial

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT05586074

  44. Study The Impact of Artificial Intelligence-Assisted Health Education on Patients' Intention to Participate in Clinical Trials: A Cluster-Randomised Controlled Trial

    Lead investigator
    Fuling Zhou · Dean, School of Nursing, Wuhan University; Tenured Full Professor, Director of Department of Hematology, zhongnan Hospital,Wuhan University
    Hospital
    Zhongnan Hospital of Wuhan University
    Status
    Recruiting
    Registry
    NCT07305337

  45. Study The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia

    Lead investigator
    Shen yang · Chief physician
    Hospital
    Ruijin Hospital
    Status
    Recruiting
    Registry
    NCT06458257

  46. Study A Multicenter, Open, Dose Escalation and Dose Expansion Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT05947344

  47. Study A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia

    Hospital
    Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
    Status
    Recruiting
    Registry
    NCT07743112

  48. Study CD180 CART Cell Injection in the Treatment of Relapsed or Refractory CD180 Positive Hematologic Malignancies: a Prospective, Single-arm, Single-center Clinical Study.

    Hospital
    Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
    Status
    Recruiting
    Registry
    NCT07106749

  49. Study Phase I Clinical Trial Protocol for Tolerability and Pharmacokinetics of TQB3455 Tablets in Patients With Hematological Malignancies

    Hospital
    Peking University People's Hospital
    Status
    Recruiting
    Registry
    NCT06550713

  50. Study To Evaluate Safety and Efficiency of AZA Combined With Chidamide as Maintenance Therapy in High-risk Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation：A Multicenter, Single-arm Study

    Hospital
    Nanfang Hospital
    Status
    Recruiting
    Registry
    NCT05270200

  51. Study A Prospective,Randomized,and Comparative Study on the Efficacy of Venetoclax Combined With CACAG Regimen and BAT Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

    Lead investigator
    Daihong Liu · doctor
    Hospital
    Chinese PLA General Hospital
    Status
    Recruiting
    Registry
    NCT06084819

  52. Study A Phase 2, Multicenter, Single-arm, Open-label Study on the Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia

    Hospital
    Anhui Provincial Hospital
    Status
    Recruiting
    Registry
    NCT06224257

  53. Study A Phase I Clinical Study on the Safety, Tolerability, and Efficacy of KSV01 Injection in Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

    Lead investigator
    He Huang · Clinical Professor
    Hospital
    The First Affiliated Hospital, Zhejiang University School of Medicine
    Status
    Recruiting
    Registry
    NCT07246707

  54. Study An Open-label, Multi-center, Phase I Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IBR733 Cell Injection in Acute Myeloid Leukemia

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT06234904

  55. Study An Exploratory Study on Targeted CD22/CD19 Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy for Enhanced Consolidation Therapy of Standard-risk B-cell Acute Lymphoblastic Leukemia

    Lead investigator
    Liping Dou · Director
    Hospital
    Chinese PLA General Hospital
    Status
    Recruiting
    Registry
    NCT07575919

  56. Study Multicenter, Randomized Controlled Clinical Study on Early Application of Realgar-Indigo Naturalis Formula (RIF) for Treatment of Acute Promyelocytic Leukemia (APL)

    Hospital
    The First Affiliated Hospital of Xi'an Jiaotong University
    Status
    Recruiting
    Registry
    NCT07503730

  57. Study Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia：Phrase II, Exploratory Study

    Hospital
    The First Affiliated Hospital, Zhejiang University School of Medicine
    Status
    Recruiting
    Registry
    NCT07105579

  58. Study Clinical Trial for the Safety and Efficacy of CAR-T Cells Therapy for Patients With the Central Nervous System Involvement of Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia or B-cell Non-Hodgkin's Lymphoma

    Lead investigator
    He Huang · Clinical Professor
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT04532203

  59. Study PA3-17 Injection for the Treatment of Subjects With Relapsed/Refractory T-Lymphoblastic Leukemia/Lymphoma: A Single-Arm, Open-Label Phase II Clinical Trial

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT07188610

  60. Study A Phase I Dose-Escalation and Phase II Study of Nanobody-Based CD19/CD22 Tandem Dual Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

    Lead investigator
    Xiao-Jun Huang · Director of Peking University Institute of Hematology
    Hospital
    Peking University People's Hospital
    Status
    Recruiting
    Registry
    NCT06880913

  61. Study Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for Relapsed/refractory Acute Myeloid Leukemia

    Lead investigator
    Xiao-Ning Gao · Chief Physician
    Hospital
    Chinese PLA General Hospital
    Status
    Recruiting
    Registry
    NCT06741722

  62. Study A Phase 1, Open-label, Multicentre Study Evaluating the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics, and Preliminary Efficacy of CG009301 for Injection in Adult Subjects With Relapsed or Refractory Haematological Malignancies

    Hospital
    The First Affiliated Hospital of Nanchang University
    Status
    Recruiting
    Registry
    NCT07347171

  63. Study A Phase I/II Single-center Study Evaluating the Safety and Efficacy of BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in Adults With Refractory/Relapsed B-cell Acute Lymphoblastic Leukaemia

    Lead investigator
    Han weidong · Director of Biotherapeutic Department
    Hospital
    First Hospital of China Medical University
    Status
    Recruiting
    Registry
    NCT07008885

  64. Study A Prospective, Multicenter Clinical Study on The Safety and Efficacy of Avapritinib in The Treatment of Relapsed/Refractory Pediatric Core Binding Factor Acute Myeloid Leukemia (CBF-AML) With KIT Mutation

    Lead investigator
    Shaoyan Hu · Study Chair
    Hospital
    Anhui Provincial Hospital
    Status
    Recruiting
    Registry
    NCT06316960

  65. Study The Efficacy and Safety of Third Generation Tyrosine Kinase Inhibitors Combined With Azacitidine and B-cell Lymphoma-2 Inhibitor in Patients With Myeloid Blast Phase Chronic Myeloid Leukemia

    Lead investigator
    Qian Jiang · Professor
    Hospital
    Peking University People's Hospital
    Status
    Recruiting
    Registry
    NCT06390306

  66. Study The Safety and Efficay Investigation of IL-5 CAR-T Cell Therapy for Patients With Refractory/Relapsed Eosinophilic Leukemia

    Lead investigator
    He Huang · Clinical Professor
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT07257640

  67. Study The Efficacy and Safety of VA Alternating With Low-dose CHA in the Treatment of Newly Diagnosed Unfit AML: a Prospective, Multi-centers, Single Arm Phase II Study

    Lead investigator
    Jie Sun · Principle Attending, Associated Professor
    Hospital
    Beijing Chao-Yang Hospital, Capital Medical University
    Status
    Recruiting
    Registry
    NCT07172204

  68. Study An Exploratory Clinical Study of CAR-T Cell Immunotherapy Using Polymer-lipid Particles to Deliver CAR1920 mRNA Targeting CD19/CD20 for Thetreatment of Relapsed/Refractory B-cell Lymphoma/Leukemia

    Lead investigator
    Daihong Liu · Dr.
    Hospital
    Chinese PLA General Hospital
    Status
    Recruiting
    Registry
    NCT07321301

  69. Study Blinatumomab Sequential Donor Lymphocyte Infusion in Acute B Lymphocytic Leukemia Observation of Therapeutic Effect in Patients With Recurrence After Allogeneic Hematopoietic Stem Cell Transplantation

    Lead investigator
    Suping ZHANG · visiting staff
    Hospital
    First Affiliated Hospital of Zhengzhou University
    Status
    Recruiting
    Registry
    NCT06339775

  70. Study A Preliminary Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetic Profile of KQ-2002 (CD19/CD22 CAR-T) in Adults With Recurrent or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

    Lead investigator
    Rong Tao · Chief physician
    Hospital
    The First Affiliated Hospital of Nanchang University
    Status
    Recruiting
    Registry
    NCT06445803

  71. Study Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT07284927

  72. Study A Phase Ib/II, Open-Label, Dose-Escalation and Cohort Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PBSS1113 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

    Hospital
    The First Affiliated Hospital, Zhejiang University School of Medicine
    Status
    Recruiting
    Registry
    NCT07761533

  73. Study A Phase 1 Study of ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies.

    Hospital
    Anhui Provincial Hospital
    Status
    Recruiting
    Registry
    NCT06656494

  74. Study Dose Escalation Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Decitabine and Cytarabine (D-CMG) for the Treatment of Elderly Newly Diagnosed Acute Myeloid Leukemia (AML) Patients

    Lead investigator
    Bing, Xu · Principal Investigator
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT06651866

  75. Study The First Affiliated Hospital, Zhejiang University School of Medicine

    Lead investigator
    He Huang · The President of the First Affiliated Hospital, Zhejiang University School of Medicine
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT06076226

  76. Study The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk Core-binding-factor Acute Myeloid Leukemia

    Lead investigator
    Shen yang · Chief physician
    Hospital
    Ruijin Hospital
    Status
    Recruiting
    Registry
    NCT06458244

  77. Study A Multicenter, Single-Arm, Prospective Clinical Study of Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia

    Lead investigator
    Xiao-Jun Huang · Prof.
    Hospital
    Peking University People's Hospital
    Status
    Recruiting
    Registry
    NCT06869265

  78. Study An Early Exploratory Clinical Study of the Safety, Tolerability and Preliminary Efficacy of JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma/Leukaemia

    Lead investigator
    Jia Wei · professor
    Hospital
    Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
    Status
    Recruiting
    Registry
    NCT06689917

  79. Study An Exploratory Study on the Safety and Efficacy of Luspatercept in the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia

    Lead investigator
    Liang Zhao · Professor
    Hospital
    Zhujiang Hospital of Southern Medical University
    Status
    Recruiting
    Registry
    NCT07362095

  80. Study A Single-arm, Prospective Study of a Cladribine-Bridged Lisaftolax and Busulfan Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia in Elderly Patients

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT07500753

  81. Study A Prospective, Multicenter, and Exploratory Study of Mitoxantrone Liposomes, Cytarabine and G-CSF Combined With Vineclavone in the Treatment ofRecurrent Adult AML and MDS-EB-2/Elder AML

    Hospital
    Ruijin Hospital
    Status
    Recruiting
    Registry
    NCT06329999

  82. Study Prospective Randomized Study of the Effectiveness and Safety of Chemotherapy Protocols Containing Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3)

    Lead investigator
    HuangMeiJuan · Chief Physician
    Hospital
    Fujian Medical University Union Hospital
    Status
    Recruiting
    Registry
    NCT07561892

  83. Study Predicting Patient Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: A Comparison of Measurable Residual Disease (MRD) Assessment by Digital Polymerase Chain Reaction and Conventional MRD

    Lead investigator
    Xiao-Jun Huang · Professor
    Hospital
    Peking University People's Hospital
    Status
    Recruiting
    Registry
    NCT06211166

  84. Study A Single-Arm, Multicenter, Open-Label, Dose- Escalating and Expanding,Phase I/II Study of SKLB1028 Combined With "7+3" Standard Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

    Hospital
    West China Hospital, Sichuan University
    Status
    Recruiting
    Registry
    NCT05445154

  85. Study Study on the Efficacy and Safety of VMAC Combined With Donor Lymphocyte Infusion (DLI) in the Treatment of Patients With Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

    Hospital
    Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
    Status
    Recruiting
    Registry
    NCT06447090

  86. Study A Multi-center Prospective Single Arm Clinical Study of Prolonged Ultra Low-dose Decitabine Combined With Venetoclax (Bcl-2 Inhibitor) as First Line Treatment for Elderly Acute Myeloid Leukemia and High-risk Myelodysplastic Syndromes

    Lead investigator
    Weiyan Zheng · Clinical Professor
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT06046313

  87. Study Super-universal CD7 CART (supCD7 CART) Cell Injection in the Treatment of Relapsed or Refractory CD7 Positive Hematologic Malignancies: a Prospective, Single-arm, Single-center Clinical Study.

    Hospital
    Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
    Status
    Recruiting
    Registry
    NCT07153068

  88. Study A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haploidentical Hematopoietic Stem Cell Transplantation Using a TBI or TMLI Conditioning Regimen for Pediatric Acute Lymphoblastic Leukemia

    Lead investigator
    Xiangbo Wan · Professor
    Hospital
    First Affiliated Hospital of Zhengzhou University
    Status
    Recruiting
    Registry
    NCT06559345

  89. Study The Significance of Serum Ferritin in the Diagnosis, Differential Diagnosis, and Prognosis of Immune-related Adverse Event (irAE)

    Hospital
    Tianjin Medical University Cancer Institute & Hospital
    Status
    Recruiting
    Registry
    NCT06702566

  90. Study Safety and Efficacy of Universal Off-the-shelf CAR-NK Cells Targeted CD123 (JD123 Injection) in the Treatment of Refractory or Relapsed CD123-positive Acute Myeloid Leukemia

    Lead investigator
    Xiao-Jun Huang · Professor
    Hospital
    Peking University People's Hospital
    Status
    Recruiting
    Registry
    NCT06201247

  91. Study Exploratory Clinical Study of JAK1 Inhibitor Golidocitnib in the Treatment of Relapsed/Refractory Indolent T/NK-Cell Lymphomas：An Open, Prospective, Exploratory Clinical Trial

    Hospital
    Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
    Status
    Recruiting
    Registry
    NCT06716658

  92. Study A Single-Center, Prospective, Single-Arm Phase II Clinical Study of Consolidation With High-Dose Cytarabine Following Deep Molecular Remission Induced by Gilteritinib Plus VA Regimen in Newly Diagnosed Intermediate-Risk Fit AML Patients With FLT3-ITD Mutation

    Lead investigator
    Jie Sun · Principle Attending, Associated Professor
    Hospital
    The First Affiliated Hospital, Zhejiang University School of Medicine
    Status
    Recruiting
    Registry
    NCT07259707

  93. Study A Clinical Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for B-Cell Acute Lymphoblastic Leukemia(B-ALL) Patients in First Complete Remission (CR1)，Minimal Residual Disease(MRD) Positive

    Lead investigator
    Jin Wang · chief physician, MD, PhD
    Hospital
    Ruijin Hospital
    Status
    Recruiting
    Registry
    NCT06718244

  94. Study Donor Derived CD117 CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

    Lead investigator
    He Huang · Principal Investigator
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT07144020

  95. Study CD123-Targeted CD16 Antibody-Modified NK Cell Immunotherapy for Refractory/Relapsed Acute Myeloid Leukemia (R/R AML)

    Lead investigator
    Chunji Gao · Principal Investigator
    Hospital
    Chinese PLA General Hospital
    Status
    Recruiting
    Registry
    NCT06835140

  96. Study A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

    Hospital
    Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
    Status
    Recruiting
    Registry
    NCT06880354

  97. Study CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia: a Prospective, Single-arm, Single-center, Phase 2 Clinical Trial

    Lead investigator
    LIANG WANG · Director of the department of hematology
    Hospital
    Beijing Tongren Hospital
    Status
    Recruiting
    Registry
    NCT06081478

  98. Study Prospective, Multicenter, Real-world Study of Dolasetron Mesylate Injection for the Prevention of Chemotherapy-induced Nausea and Vomiting in Children With Acute Lymphoblastic Leukemia

    Lead investigator
    Tianping Chen · Associate chief physician
    Hospital
    Anhui Provincial Children's Hospital
    Status
    Recruiting
    Registry
    NCT06756022

  99. Study A Phase II/III Study of ICP-248 in Combination With Orelabrutinib in Patients With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT06378138

  100. Study Tracjectories and Predictors of Chemotherapy Induced Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia: A Perspective Longitudinal Study

    Lead investigator
    Dr Eva Ho · Associate professor
    Hospital
    Henan Cancer Hospital
    Status
    Recruiting
    Registry
    NCT07326930

  101. Study A Multicenter, Randomized, Open-Label, Phase III Clinical Study to Evaluate the Efficacy and Safety of HMPL-306 vs. Salvage Chemotherapy Regimens in Patients With IDH1- and IDH2-mutated Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT06387069

  102. Study A Multicenter, Prospective, Single-Arm Study of Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    Lead investigator
    Bing, Xu · Dr. Bing Xu
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT07783100

  103. Study A Clinical Study to Explore the Safety, Efficacy, and Pharmacokinetics of CT0596 CAR-T Cell Injection in Patients With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia

    Status
    Recruiting
    Registry
    NCT06718270

  104. Study Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia

    Lead investigator
    Shuhong Shen · Chair of hematology oncology department of SCMC
    Hospital
    Anhui Provincial Children's Hospital
    Status
    Recruiting
    Registry
    NCT06607419

  105. Study A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.

    Hospital
    Peking University People's Hospital
    Status
    Recruiting
    Registry
    NCT06927466

  106. Study Safety and Efficacy Study of Demethylating Agents With Venetoclax in Preventing Recurrence of High-risk T-cell Lymphoblastic Lymphoma/Leukemia After Transplantation

    Lead investigator
    Xianmin Song, MD · Professor
    Hospital
    Shanghai General Hospital
    Status
    Recruiting
    Registry
    NCT06686108

  107. Study A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Hospital
    Peking Union Medical College Hospital
    Status
    Recruiting
    Registry
    NCT06973187

  108. Study A Randomized, Controlled, Double-Blind, Multicenter, Phase Ⅲ Study to Evaluate the Efficacy and Safety of IMM01 (Timdarpacept) in Combination With Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)

    Hospital
    Anhui Provincial Hospital
    Status
    Recruiting
    Registry
    NCT06647862

  109. Study Clinical Study on the Safety and Efficacy of CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.

    Hospital
    Guangzhou Women and Children's Medical Center
    Status
    Recruiting
    Registry
    NCT06752785

  110. Study The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With Relapsed or Refractory B-lymphoblastic Leukemia

    Lead investigator
    Xiaoyu Zhu · Chief Prof.
    Hospital
    Anhui Provincial Hospital
    Status
    Recruiting
    Registry
    NCT06307600

  111. Study A Single-center, Single-arm, Prospective Clinical Study of Intermediate-dose Cytarabine in Combination With Venetoclax for Consolidation Therapy of Middle- and High-risk Acute Myeloid Leukemia in The Elderly

    Lead investigator
    Yehui Tan · Professor
    Hospital
    The First Hospital of Jilin University
    Status
    Recruiting
    Registry
    NCT06990321

  112. Study Phase 2 Trial of Menin Inhibitor BN104 as Post Hematopoietic Stem Cell Transplantation Maintenance in Patients With Acute Leukemia

    Lead investigator
    Chen Suning · Prof.
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT07101497

  113. Study A Prospective, Randomized Controlled Clinical Study on the Efficacy and Safety of the TmBU Regimen Versus mBUCY Regimen for Conditioning Before Allo-HSCT in High-risk or Relapsed/Refractory Acute Leukemia

    Lead investigator
    Sheng-Li Xue, MD · Prof.
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT06816134

  114. Study A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BL-M11D1 in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients

    Hospital
    Anhui Provincial Hospital
    Status
    Recruiting
    Registry
    NCT05924750

  115. Study Prospective Single-Arm Clinical Study of Thiotepa-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia

    Lead investigator
    Sun Yuqian · Principal Investigator
    Hospital
    Peking University People's Hospital
    Status
    Recruiting
    Registry
    NCT07588594

  116. Study A Novel Post-transplant Regimen of PT/FLU+CY for Selectively Promoting Unrelated Cord Blood Engraftment in Haploidentical-cord Transplantation in Childhood Leukemia: a Single-arm, Multi-center Trial

    Hospital
    Nanfang Hospital
    Status
    Recruiting
    Registry
    NCT06155188

  117. Study A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)

    Hospital
    Second Xiangya Hospital of Central South University
    Status
    Recruiting
    Registry
    NCT05254743

  118. Study A Single-arm, Dose-escalation and Dose-expansion Phase I Clinical Study to Evaluate the Tolerability, Safety and Preliminary Efficacy of BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

    Hospital
    Zhujiang Hospital of Southern Medical University
    Status
    Recruiting
    Registry
    NCT06118788

  119. Study A Prospective, Multicenter, Randomized Controlled Study on the MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

    Hospital
    First Affiliated Hospital of Zhengzhou University
    Status
    Recruiting
    Registry
    NCT06345365

  120. Study A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    Hospital
    China-Japan Friendship Hospital
    Status
    Recruiting
    Registry
    NCT06943872

  121. Study A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy

    Hospital
    Peking University First Hospital
    Status
    Recruiting
    Registry
    NCT06852222

  122. Study A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

    Hospital
    Shenzhen People's Hospital
    Status
    Not yet recruiting
    Registry
    NCT07676006

  123. Study Clinical Study on the Safety and Efficacy of QH101 in Patients With Relapsed/Refractory Acute Myeloid Leukemia(R/R AML) and Relapsed/Refractory Myelodysplastic Syndromes(R/R MDS)

    Lead investigator
    Xiaoyu Zhu · Director of Hematology Department
    Hospital
    Anhui Provincial Hospital
    Status
    Not yet recruiting
    Registry
    NCT07131085

  124. Study A Multicenter, Prospective Clinical Study of Olverembatinib Combined With Blinatumomab in the Treatment of Adult de Novo Philadelphia Chromosome Positive Acute Lymphoid Leukemia

    Lead investigator
    Chen Suning · Principal Investigator
    Hospital
    First Affiliated Hospital of Soochow University
    Status
    Not yet recruiting
    Registry
    NCT05931757

  125. Study Single-Arm, Multicenter, Prospective Phase II Clinical Study of Rituximab Combined With Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for Richter Syndrome Transformed From Chronic Lymphocytic Leukemia

    Hospital
    Henan Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT07831395

  126. Study Comparing the Efficacy and Safety of Decitabine-Fludarabine-busulfan (Dec-FB4) and Fludarabine-busulfan (FB4) as Conditioning Regimens for AML-MR

    Lead investigator
    Hu Xiaoxia · Principal Investigator
    Hospital
    Ruijin Hospital
    Status
    Not yet recruiting
    Registry
    NCT06297772

  127. Study A Prospective, Multicenter, Randomized Controlled, Open Label, Non-Inferiority Study Comparing the Efficacy and Safety of the VA Regimen (Venetoclax Combined With Azacitidine) With the "3+7" Regimen in the Treatment of Newly Diagnosed AML Patients With NPM1 or IDH1/IDH2 Mutations

    Lead investigator
    Shen yang · Chief Physician, Professor, Department of Hematology
    Hospital
    Ruijin Hospital
    Status
    Not yet recruiting
    Registry
    NCT07664839

  128. Study A Phase 1b/2 Study of AK117 (Anti-CD47 Antibody) in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia

    Hospital
    Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
    Status
    Not yet recruiting
    Registry
    NCT06387420

  129. Study A Clinical Study to Investigate the Safety and Efficacy of CT0991 in Patients With Relapsed/Refractory Acute Myeloid Leukemia.

    Lead investigator
    MEI HENG · Principal Investigator
    Hospital
    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Status
    Not yet recruiting
    Registry
    NCT07233018

  130. Study Effectiveness and Safety of Inotuzumab Ozogamicin±Donor Lymphocyte Infusion for Relapsed B Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma After Allogeneic Hematopoietic Stem Cell Transplantation：Phrase II, Multicenter Study

    Lead investigator
    Yi Luo · Clinical Professor
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Not yet recruiting
    Registry
    NCT06861348

  131. Study A Prospective, Multicenter, Open-label, Randomized Controlled Trial of SHR2554 Plus Azacitidine in Overlapped Sequential Combination With Modified BUCY Conditioning Regimen in Patients With High-risk or Relapsed/Refractory Acute Leukemia and Myelodysplastic Neoplasms Secondary IDs

    Lead investigator
    Limin Liu,MD · Principal Investigator
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Not yet recruiting
    Registry
    NCT07575412

  132. Study Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

    Lead investigator
    Donghua Zhang · professor
    Hospital
    Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
    Status
    Not yet recruiting
    Registry
    NCT07342244

  133. Study Assessment of the Safety and Efficacy of Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia: A Single-Arm, Open-Label, Prospective Study

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Not yet recruiting
    Registry
    NCT06559644

  134. Study An Early Exploratory Clinical Study on the Safety, Tolerability, and Preliminary Efficacy of JY231 Injection in the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)

    Lead investigator
    He Huang · Professor, Director of the Bone Marrow Transplantation Center
    Hospital
    The First Affiliated Hospital, Zhejiang University School of Medicine
    Status
    Not yet recruiting
    Registry
    NCT06902025

  135. Study Phase I Clinical Study of CD19-targeting Chimeric Antigen Receptor T Lymphocyte (MC-1-50) for the Treatment of Relapsed/Refractory CD19-positive B-cell Acute Lymphoblastic Leukemia (B-ALL)

    Hospital
    Ruijin Hospital
    Status
    Not yet recruiting
    Registry
    NCT06641024

  136. Study A Multicenter Prospective Study on Structuralized Follow-up Model Construction and Late Effect Burden of Childhood Hematological Malignancy Survivors (HEM-SURVIVE)

    Lead investigator
    zhangjingying · Principal Investigator
    Hospital
    Children's Hospital Zhejiang University School of Medicine
    Status
    Not yet recruiting
    Registry
    NCT07483749

  137. Study A Single-Arm, Prospective Clinical Study of the Efficacy and Safety of VABu Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Non-High-Risk AML Patients in CR1 With Low Performance Status (ECOG ≥ 2) or High Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI ≥ 2)

    Hospital
    First Affiliated Hospital of Soochow University
    Status
    Not yet recruiting
    Registry
    NCT07762508

  138. Study An Exploratory Clinical Study Evaluating the Safety and Pharmacokinetic Profile of SNC116 in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

    Hospital
    The First Hospital of Jilin University
    Status
    Not yet recruiting
    Registry
    NCT07830238

  139. Study A Multicenter, Open-Label, Phase 1/2 Clinical Study of the Safety and Efficacy of Aclarubicin Combined With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia

    Lead investigator
    Junmin Li · Chief Physician of hematology
    Hospital
    Ruijin Hospital
    Status
    Not yet recruiting
    Registry
    NCT07486726

  140. Study Efficacy and Safety of Maintenance Treatment With Chidamide, Venetoclax, and Azacitidine for Treatment-Naive Acute Myeloid Leukemia Patients Achieving Complete Remission: A Multicenter Study

    Hospital
    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Status
    Not yet recruiting
    Registry
    NCT07521124

  141. Study A Multicenter, Open, Single-arm Phase I Dose-escalation and Dose-expansion Clinical Study: Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of FXS0683 Tablets in Patients With Relapsed or Refractory Hematologic Malignancies.

    Hospital
    Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
    Status
    Not yet recruiting
    Registry
    NCT07616089

  142. Study A Prospective Study on the Efficacy and Safety of Venetoclax, Azacitidine, and Homoharringtonine (VAH) Combination as a Bridging Regimen to Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Acute Myeloid Leukemia

    Hospital
    Ruijin Hospital
    Status
    Not yet recruiting
    Registry
    NCT07091006

  143. Study Efficacy and Safety of Zanubrutinib, Obinutuzumab, and Bendamustine (ZGB) Regimen for First-Line Treatment of Chronic Lymphocytic Leukemia: A Single-Arm, Prospective Study

    Lead investigator
    Ou Bai, MD/PHD · Director
    Hospital
    The First Hospital of Jilin University
    Status
    Not yet recruiting
    Registry
    NCT07003464

  144. Study A Prospective, Open-Label, Single-Arm, Two-Cohort Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Bcl-2 Inhibitor Combined With Azacitidine in the Treatment of Newly Diagnosed Mixed Phenotype Acute Leukemia

    Lead investigator
    Chen Suning · Doctor
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Not yet recruiting
    Registry
    NCT07573670

  145. Study This is a Multicenter, Retrospective Real-world Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China

    Lead investigator
    Xiao-Jun Huang · Prof.
    Hospital
    Peking University People's Hospital
    Status
    Not yet recruiting
    Registry
    NCT06557304

This page only shares publicly registered study information. It does not recommend or encourage joining any study. Participation is entirely voluntary and the risks of an unapproved treatment are unknown; contact the hospital directly for eligibility and informed-consent details.

Advanced therapies: what is licensed and what is in trials

Hospitals with a national key specialty record

Show the hospital records 21 hospitals with a key-specialty record

Each row is a hospital with a national key clinical specialty record in a specialty this condition is filed under. This is a record of published listings, not a recommendation and not a ranking.

Hospital City Specialty (as published) Evidence Source
Ruijin Hospital上海交通大学医学院附属瑞金医院
Tier 3 · HIGHEST
 Shanghai 上海市 Hematology 血液科 Level B https://www.rjh.com.cn/2018RJPortal/lcyxy2019/sy/jj/index.shtml
Beijing Hospital北京医院
Tier 3 · HIGHEST
 Beijing 北京市 Hematology 血液科 Level B https://www.bjhmoh.cn/index.php?id=4&r=archives/about&t=1790009033
Peking University People's Hospital北京大学人民医院 Beijing 北京市 Hematology 血液科 Level B https://www.pkuph.cn/news_details/26715.html
Peking University Third Hospital北京大学第三医院 Beijing 北京市 Hematology 血液内科 Level B https://www.puh3.net.cn/yygk/zdxk.htm
West China Hospital, Sichuan University四川大学华西医院
Tier 3 · HIGHEST
 Chengdu 成都市 Hematology 血液内科 Level A https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
Anhui Provincial Hospital中国科学技术大学附属第一医院（安徽省立医院） Hefei 合肥市 Hematology 血液内科 Level B https://www.ahslyy.com.cn/nanqu/col456/892156
Qilu Hospital of Shandong University山东大学齐鲁医院
Tier 3 · HIGHEST
 Jinan 济南市 Hematology 血液内科 Level A http://wsjkw.shandong.gov.cn/wmfw/cxfw/202307/P020230717441794577839.xlsx
Sun Yat-sen Memorial Hospital, Sun Yat-sen University中山大学孙逸仙纪念医院 Guangzhou 广州市 Hematology 地方病科（儿科血液） Level B https://www.gzsys.org.cn/basic/453
The First Affiliated Hospital, Sun Yat-sen University中山大学附属第一医院 Guangzhou 广州市 Hematology 血液内科 Level B https://gcp.fahsysu.org.cn/sites/1h.gcp.sysucloud1.sysu.edu.cn/files/2023-07/20230625%20中山大学附属第一医院宣传折页%20V5.0_0.pdf
Nanfang Hospital南方医科大学南方医院 Guangzhou 广州市 Hematology 血液内科 Level B https://www.nfyy.com/index.html
Guangzhou First People's Hospital广州市第一人民医院
Tier 3 · HIGHEST
 Guangzhou 广州市 Hematology 血液内科 Level B https://oa.gzhosp.cn/col40/list_5
Jiangsu Province Hospital江苏省人民医院（南京医科大学第一附属医院）
Tier 3 · HIGHEST
 Nanjing 南京市 Hematology 血液内科 Level B https://www.jsph.org.cn/info/3571/72851.htm
The First Affiliated Hospital, Zhejiang University School of Medicine浙江大学医学院附属第一医院
Tier 3 · HIGHEST
 Hangzhou 杭州市 Hematology 血液内科 Level A http://zdygb.zju.edu.cn/2014/0106/c34026a1762975/page.htm
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology华中科技大学同济医学院附属协和医院 Wuhan 武汉市 Hematology 血液科 Level B https://www.whuh.com/Science/major/gjlczdzkb/2.htm
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology华中科技大学同济医学院附属同济医院
Tier 3 · HIGHEST
 Wuhan 武汉市 Hematology 血液内科 Level B https://www.tjh.com.cn/contents/934/27291.html
Third Xiangya Hospital中南大学湘雅三医院
Tier 3 · HIGHEST
 Changsha 长沙市 Hematology 血液内科 Level B https://www.xy3yy.com/ksjj/184173.html
Second Xiangya Hospital of Central South University中南大学湘雅二医院 Changsha 长沙市 Hematology 血液内科 Level B https://www.xyeyy.com/655/656/664/
Xiangya Hospital of Central South University中南大学湘雅医院
Tier 3 · HIGHEST
 Changsha 长沙市 Hematology 血液内科 Level B https://www.xiangya.com.cn/zdzk.html
Hunan Cancer Hospital湖南省肿瘤医院
Tier 3 · HIGHEST
 Changsha 长沙市 Hematology 淋巴血液肿瘤专科（国家级培育项目） Level B https://hnca.org.cn/wap/zdks/
The First Affiliated Hospital of Chongqing Medical University重庆医科大学附属第一医院 Chongqing 重庆市 Hematology 血液内科 Level B https://www.hospital-cqmu.com/gzb/yygk/yyjj.htm
The First Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院
Tier 3 · HIGHEST
 Xi'an 西安市 Hematology 血液内科 Level B http://www.dyyy.xjtu.edu.cn/gzbsy/zdxk.htm

21 hospitals with a matching national key specialty record.

Values written in Chinese are quoted as published by the source.

What patients report

Aggregate figures only: a national result quoted with its source and the year it refers to. This is not a patient testimonial and not a statement about one person.

  • As reported in National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) (2023): National inpatient satisfaction / outpatient satisfaction — 95.42 / 93.95 score, 0-100.

    National aggregate across the 2,168 tertiary public hospitals that took part in the national performance monitoring (all conditions combined; not disease-specific, not hospital-specific).

    Source: National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) — https://www.gov.cn/zhengce/zhengceku/202503/content_7016208.htm — 2023 — Level A

All therapy & access topics

Questions about this condition

We cannot give medical advice, but we can answer questions about this page and about arranging treatment in China.

Ask us about this condition

ICD codes

Show the code table 5 ICD codes
Version Code Name in that version
ICD-10-WHO C91 Lymphoid leukaemia
ICD-10-WHO C92 Myeloid leukaemia
ICD-10-WHO C93 Monocytic leukaemia
ICD-10-WHO C94 Other leukaemias of specified cell type
ICD-10-WHO C95 Leukaemia of unspecified cell type

Rows are the WHO ICD-10 entries for this condition, quoted as published.

Source & evidence

Source URL
https://www3.ha.org.hk/cancereg/tc/icd10.html
Source scheme
https
Source type
Third-party compilation
Evidence level
A - stated by a health commission, a national research institute or a university
Retrieved on
2026-10-01